Scarica l'app Stockscreener
2.13
12.35%
-0.30
Dopo l'orario di chiusura:
2.13
Processa Pharmaceuticals Inc Borsa (PCSA) Ultime notizie
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com Nigeria
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
Processa Pharmaceuticals Inc - TradingKey
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) grants director 33,500 RSUs and reports option stake - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.490|Chg%:-0.010 - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.600|Chg%:-0.270 - TradingKey
PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline ProgressTax Rate Impact - dars.gov.et
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates, No Revenue ReportedOperating Margin Analysis - dars.gov.et
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com South Africa
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting - Stock Titan
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award - Stock Titan
PCSA Q4 2025 Earnings: Wider-Than-Expected EPS Loss Amid Pipeline DevelopmentAnnual Report - dars.gov.et
PCSA Q4 2025 Earnings: Wider-than-Expected Loss Highlights Clinical Stage ChallengesEarnings Turnaround - dars.gov.et
Enterprise value to EBIT forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to sales forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to book forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to earnings forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Enterprise value to revenue forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA) - TradingView
PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay - Stock Titan
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):